In clinical trials2,3Evidence: Large human trialsMetabolic and weight

Cotadutide2

Key takeaway

Cotadutide is a synthetic peptide that activates both the GLP-1 and glucagon receptors, recorded in FDA’s substance registry.2,3 In a randomized Phase 2b trial of 834 adults with type 2 diabetes and overweight or obesity, it lowered blood sugar (HbA1c) and body weight more than placebo over 54 weeks; nausea and vomiting were its most common side effects.3 No FDA approval is reported in the sources reviewed here, and cotadutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6

Cotadutide at a glance

What it isA synthetic dual GLP-1 and glucagon receptor agonist peptide, recorded as cotadutide in FDA’s substance registry.2,3
FDA statusNot FDA-approved. None of the sources reviewed here reports an approval of cotadutide.2,3
Human evidenceA randomized Phase 2b trial in 834 adults with type 2 diabetes and overweight or obesity, published in 2021.3
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is cotadutide?

Cotadutide is a synthetic peptide recorded in FDA’s substance registry. The 2021 trial authors describe it as a dual GLP-1 and glucagon receptor agonist under development for liver disease and for kidney disease with type 2 diabetes.2,3

How is cotadutide thought to work?

It acts on two hormone receptors, those for GLP-1 and for glucagon. The trial authors studied whether this combination improves blood sugar, weight and liver measures.3

What do human studies show?

The 2021 Phase 2b trial randomized 834 adults with type 2 diabetes not controlled by metformin to one of three strengths of cotadutide, placebo or open-label liraglutide, and continued treatment for 54 weeks.3

Cotadutide lowered HbA1c and body weight significantly more than placebo at 14 and 54 weeks. The highest strength also improved liver enzymes and liver fibrosis scores, which liraglutide did not.3

Nausea (35%) and vomiting (17%) were the most common adverse events with cotadutide, and they decreased over time.3

ClinicalTrials.gov lists a Phase 2 trial in non-cirrhotic steatohepatitis with fibrosis (NCT05364931) as completed in its September 3, 2025 record.1

What the evidence base contains

  • Large randomized human trial A randomized Phase 2b trial in 834 adults with type 2 diabetes and overweight or obesity, comparing three strengths of cotadutide with placebo and open-label liraglutide over 54 weeks (2021).3

Evidence-strength label: Large randomized human trials. How this label is assigned

Is cotadutide FDA-approved?

None of the sources reviewed here reports an approval of cotadutide by FDA.2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list cotadutide.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Cotadutide is not among them.5,6

Timeline

  1. The 54-week Phase 2b trial of cotadutide in 834 adults is published.3

What is still unknown?

Whether its liver effects translate into real benefit for liver disease: the 2021 trial measured liver biomarkers and scores in an exploratory analysis, not liver outcomes.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Cotadutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Cotadutide are a bounded selection, not every registration or paper about Cotadutide. For the years before Cotadutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Cotadutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Cotadutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; studied in clinical trials. A randomized Phase 2b trial of 834 adults found lower blood sugar and weight than placebo over 54 weeks. Cotadutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Cotadutide?

Not FDA-approved; studied in clinical trials. A randomized Phase 2b trial of 834 adults found lower blood sugar and weight than placebo over 54 weeks. Cotadutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
3
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date September 3, 2025

ClinicalTrials.gov record NCT05364931↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Cotadutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

3Selected dated records
8Connected citations
3Populated source years2020–2025
1/4Record lanes present

Registered human studies

Trial composition

3 of 3 selected trial records include at least one phase value; 3 of 3 include a status value in the retained structured contract.

PhasesPhase 1 2Phase 2 1
Status at observationCompleted 3

PubMed bibliography

Publication composition

0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
3

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 3 dated records

Research hub

Explore the Cotadutide evidence record

Open all 3 records →
3Dated records
1Evidence type
3Cited public sources
3Source years

Change ledger

Recently changed for Cotadutide

Open all 3 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03625778

PeptideScanner retained ClinicalTrials.gov record NCT03625778 at 2026-11-16T01:47:38.899Z. Its registry update date was 2021-08-23, and PeptideScanner's reviewed identity mapping was cotadutide.

PeptideScanner change date
November 16, 2026
Cited source date
August 23, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04208620

PeptideScanner retained ClinicalTrials.gov record NCT04208620 at 2026-11-16T01:47:38.899Z. Its registry update date was 2020-07-31, and PeptideScanner's reviewed identity mapping was cotadutide.

PeptideScanner change date
November 16, 2026
Cited source date
July 31, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05364931

PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.

PeptideScanner change date
November 16, 2026
Cited source date
September 3, 2025
Evidence lane
Clinical trials

Official-source collections

Source records for Cotadutide

Open the full research atlas →
ClinicalTrials.gov3

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05364931Registry update September 3, 2025 · completed at observation
  2. NCT03625778Registry update August 23, 2021 · completed at observation
  3. NCT04208620Registry update July 31, 2020 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span July 31, 2020 to September 3, 2025. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration2,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 3

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT05364931↗

    PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03625778↗

    PeptideScanner retained ClinicalTrials.gov record NCT03625778 at 2026-11-16T01:47:38.899Z. Its registry update date was 2021-08-23, and PeptideScanner's reviewed identity mapping was cotadutide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04208620↗

    PeptideScanner retained ClinicalTrials.gov record NCT04208620 at 2026-11-16T01:47:38.899Z. Its registry update date was 2020-07-31, and PeptideScanner's reviewed identity mapping was cotadutide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT05364931 · retained source version 2025-09-03:75051896cdb19d8db938ea27bd79d0e2c5663f5560fa8680f8848f0c59ba9237 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    Cotadutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  3. 3
    Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study (2021) · PMID 34016612 ↗

    Diabetes Care · Official source · Source checked November 15, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026